Log in to search using one of your social media accounts:

 

Medical News Today: Lung cancer in women: Signs and symptoms
Recent research has suggested that lung cancer affects women differently to men. We look at the types, their causes, symptoms, treatments, and outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 21, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

NICE recommends Bristol-Myers Squibb ’s nivolumab for NSCLC patients on NHS
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol-Myers Squibb ’s immunotherapy drug Opdivo (nivolumab) for NHS use through the Cancer Drugs Fund (CDF) for the treatment of advanced non-small-cell lung cancer (NSC… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 20, 2017 Category: Pharmaceuticals Source Type: news

Nurses welcome NHS approval of ‘exciting’ lung cancer drug
Oncology nurses have welcomed a draft ruling by the National Institute for Health and Care Excellence that a lung cancer drug should be made available to some patients in England. (Source: Nursing Times)
Source: Nursing Times - September 20, 2017 Category: Nursing Source Type: news

AA Gill lung cancer: Life saving drug nivolumab writer denied now approved for NHS use
A LUNG cancer drug which was denied to British writer and critic AA Gill has been approved for some patients with his type of cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - September 20, 2017 Category: Consumer Health News Source Type: news

Smoking cuts life expectancy in HIV more than AIDS does
People with HIV who smoke are 6-13 times more likely to die from lung cancer than AIDS-related causes Related items fromOnMedica Smoking cessation Government pledges to cut smoking prevalence to 12% by 2022 Smoking quit attempt numbers fall again HIV infection may make patients vulnerable to diabetes HIV life expectancy ‘near normal’ due to antiretroviral therapy (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 20, 2017 Category: UK Health Source Type: news

Life-extending lung cancer drug approved
A drug denied to restaurant critic AA Gill on the NHS will now be made available to patients in England. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 19, 2017 Category: Consumer Health News Source Type: news

Life-extending lung cancer nivolumab drug approved
The drug nivolumab, denied to writer AA Gill on the NHS, will be available to patients in England. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 19, 2017 Category: Consumer Health News Source Type: news

UK backs Opdivo for lung cancer after Bristol-Myers cuts price
LONDON (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price. (Source: Reuters: Health)
Source: Reuters: Health - September 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Smokers With HIV Face Higher Risk From Lung Cancer Than From AIDS Smokers With HIV Face Higher Risk From Lung Cancer Than From AIDS
Smokers living with HIV who consistently take antiretroviral medications may be far more likely to die of lung cancer than of AIDS, a U.S. study suggests.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 19, 2017 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

HIV and smoking a lethal combo for the lungs
HIV patients who take their medication but also smoke are about 10 times more likely to die from lung cancer than from AIDS-related causes. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 19, 2017 Category: Consumer Health News Source Type: news

Expected Burden of Lung Cancer High for People Living With HIV
PLWH who adhere to antiretroviral tx but smoke are substantially more likely to die from lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 19, 2017 Category: Cancer & Oncology Tags: Family Medicine, Infections, AIDS, Internal Medicine, Oncology, Pathology, Pulmonology, Journal, Source Type: news

New Path for Lung Cancer Treatment?
(MedPage Today) -- Targeting inflammation linked to fewer lung cancer deaths (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 18, 2017 Category: Hematology Source Type: news

Smokers with HIV face higher risk from lung cancer than from AIDS
(Reuters Health) - Smokers living with HIV who consistently take antiretroviral medications may be far more likely to die of lung cancer than of AIDS, a U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

HIV and Smoking a Lethal Combo for The Lungs
Source: HealthDay Related MedlinePlus Pages: Living with HIV/AIDS, Lung Cancer, Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 18, 2017 Category: Consumer Health News Source Type: news

HIV people who smoke more likely to die of lung cancer
Researchers from Massachusetts General Hospital studied HIV patients' risk of dying from the disease or from lung cancer. They found people were 10 times more likely to die from lung cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 18, 2017 Category: Consumer Health News Source Type: news

HIV and Smoking a Lethal Combo for the Lungs
MONDAY, Sept. 18, 2017 -- HIV patients who take their medication but also smoke are about 10 times more likely to die from lung cancer than from AIDS-related causes, a new study estimates. Lifesaving antiretroviral drugs have improved life... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 18, 2017 Category: General Medicine Source Type: news

Medical News Today: Immunotherapy for lung cancer: What you need to know
What is immunotherapy for lung cancer and how does it work? Learn about the benefits, risks, and side effects. What is the future for immunotherapy? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Medical News Today: Lung cancer and cough: What is the connection?
In this article, we look at the connection between coughing and lung cancer, including the causes of coughing, symptoms of lung cancer, and treatments. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

People with HIV who smoke are more likely to die from lung cancer than from HIV itself
(Massachusetts General Hospital) People living with HIV who adhere to antiretroviral therapy but smoke cigarettes are around 10 times more likely to die from lung cancer than from HIV itself, according to a study led by researchers at Massachusetts General Hospital. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 18, 2017 Category: Cancer & Oncology Source Type: news

Study questions value of CT scans after NCSLC surgery
Performing CT scans after surgery for non-small cell lung cancer (NSCLC) may...Read more on AuntMinnie.comRelated Reading: Study: CT screening would cut lung cancer deaths in China Multipurpose CT lung cancer screening more cost-effective Subsolid lung nodule assessment with CT evolves ARRS: Do NLST results translate to the real world? Lung-RADS category 4X helps diagnose lung cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 15, 2017 Category: Radiology Source Type: news

Larry King reveals lung cancer diagnosis
Larry King has gone public with a recent cancer diagnosis. (Source: CNN.com - Health)
Source: CNN.com - Health - September 14, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Single molecule determines lung cancer cell death
A new study finds that one molecule is key to whether or not particular lung cancer cells respond to chemotherapy and undergo programmed cell death. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 14, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Larry King says he had Stage 1 lung cancer
Larry King revealed to "Extra" host Mario Lopez that he was diagnosed with Stage 1 lung cancer (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 13, 2017 Category: Consumer Health News Source Type: news

Global Mesothelioma Deaths Remain High Despite Poor Data
An estimated 38,400 people around the world will die this year from mesothelioma cancer, according to a report recently published in Occupational & Environmental Medicine. The estimation by the international peer-reviewed journal included 230 countries. Data used for the study came from the World Health Organization’s (WHO) Mortality Database and extrapolated information based on gender- and age-specific death rates. “The global burden of mesothelioma is real,” Dr. Ken Takahashi, director of Asbestos Diseases Research Institute, University of Sydney Gate 3, Australia, told Asbestos.com. “It is v...
Source: Asbestos and Mesothelioma News - September 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Asbestos Diseases Research Institute asbestos-related lung cancer Australia mesothelioma Bangladesh Dr. Christina Fitzmaurice Dr. Ken Takahashi Global Burden of Disease Mesothelioma death rate mesothelioma latency period mesothelioma uni Source Type: news

Lung cancer warning: Carrying too much fat HERE can be deadly
LUNG cancer and gastrointestinal cancer can be caused by carrying too much fat around your middle - or abdominal - area. (Source: Daily Express - Health)
Source: Daily Express - Health - September 12, 2017 Category: Consumer Health News Source Type: news

Researchers identify possible new target in fight against lung cancer
(Boston University School of Medicine) Researchers at Boston University School of Medicine have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in the cancer cells' fate -- determining whether or not the specific subtype of cancer cell will undergo programmed cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Regulation of autophagy, NF-{kappa}B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells
KRAS mutant non–small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of the RAS pathway. Identifying alternative networks that promote survival specifically in mesenchymal NSCLC may lead to more effective treatments for this subtype. Through their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate the epithelial-mesenchymal transition (EMT...
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Mehta, A. K., Hua, K., Whipple, W., Nguyen, M.-T., Liu, C.-T., Haybaeck, J., Weidhaas, J., Settleman, J., Singh, A. Tags: STKE Research Articles Source Type: news

Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice
Several lung cancer experts from the US and Europe provide their perspective on a variety of important lung trials presented at ESMO 2017.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Medical News Today: Cigarette smoke may 'prime lung cells' to develop cancer
Using cell-based models of cigarette smoke exposure, researchers show how smoking alters gene expression over time to prime lung cells to develop cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 11, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

'Epigenetic' changes from cigarette smoke may be first step in lung cancer development
(Johns Hopkins Medicine) Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called 'epigenetic' changes in the cells consistent with the earliest steps toward lung cancer development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

Durvalumab Boots PFS Even in Stage 3 Lung Cancer Durvalumab Boots PFS Even in Stage 3 Lung Cancer
Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer
(European Society for Medical Oncology) Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

Durvalumab improves progression-free survival in stage III lung cancer
(European Society for Medical Oncology) Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

5 Ways Climate Change May Be Making Hurricanes Worse
Natural disasters were once entirely natural — and most still are. Hurricanes, however, may be a different matter. As Hurricane Irma roars toward Florida, Hurricanes Jose and Katia churn in the Atlantic Ocean and the Gulf of Mexico, and Houston picks up after Hurricane Harvey, the familiar question is being raised: what role does climate change play in all this volatility? Climate scientists say that while a definitive answer is impossible, because the climate is unfathomably complex, there is a vast and growing body of evidence that points toward global warming having an impact on the formation and severity of hurri...
Source: TIME.com: Top Science and Health Stories - September 8, 2017 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized climate climate change Environment global warming harvey Hurricanes irma ocean levels Source Type: news

AstraZeneca looks for boost from positive trials
Drugmaker looks to shrug off Mystic blow with upbeat results for lung cancer drugs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 8, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca rebuilds cancer drug hopes with new lung data
MADRID (Reuters) - Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Drinks industry accused of downplaying 'alcohol-cancer risk'
Conclusion This qualitative analysis aimed to determine the accuracy of health information circulated by the alcohol industry on the links between alcohol and cancer. It found the industry and affiliated organisations use three main approaches: denial of the link between alcohol and cancer misinterpretation of the risk distraction by focusing on other risk factors This analysis highlights how these strategies could be detrimental to public health. Of course, it's possible, given this data was collected in 2016, that some of the websites and documents analysed by the researchers have since been updated. Regardless, the...
Source: NHS News Feed - September 8, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Broncus Medical affiliate acquires Uptake Medical
Uptake Medical said yesterday that its InterVapor device for treating emphysema is back on the market in Europe after its acquisition for an undisclosed amount by an affiliate of Broncus Medical. Broncus set its purchase up under a new entity based in Seattle, Uptake Medical Technology, and plans to add markets in Australia and Asia to its commercial footprint in Europe by the end of the year. The InterVapor device uses heated water vapor to reduce lung volume in emphysema patients. Uptake won an expanded CE Mark in the European Union for InterVapor in August 2015. “2018 promises to be an exciting year for ...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Respiratory Wall Street Beat Broncus Medical Uptake Medical Source Type: news

Lung cancer: Scientists find answer to resistance
(University of Southern Denmark Faculty of Health Sciences) Scientists at the University of Southern Denmark have found a new strategy for overcoming the resistance, which many lung cancer patients develop towards a recent drug, which can arrest the growth of tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

Merck's immunotherapy, chemo mix shows extended lung cancer gains
MADRID (Reuters) - Giving Merck& Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Adding modified herpes virus to immunotherapy shows promise for treating advanced melanoma
FINDINGSIn a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment ’s side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.BACKGROUNDUCLA scientists are testing the combination of pembrolizumab (marketed as Keytruda) and T-VEC (marketed as Imlygic) as a treatment option for people with advanced melanoma tha...
Source: UCLA Newsroom: Health Sciences - September 7, 2017 Category: Universities & Medical Training Source Type: news

AI algorithm can classify bone lesions on PET/CT images
An artificial intelligence (AI) algorithm can reliably classify benign and...Read more on AuntMinnie.comRelated Reading: Hybrid modalities disappoint in bone metastases accuracy How to develop deep-learning algorithms for radiology AI can obviate biopsies of indolent thyroid nodules Luminal water MRI could be best for prostate cancer CAD finds vertebral lung cancer metastases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 7, 2017 Category: Radiology Source Type: news

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p (Source: Roche Media News)
Source: Roche Media News - September 6, 2017 Category: Pharmaceuticals Source Type: news

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2017 Category: Pharmaceuticals Source Type: news

Blood tumor markers may warn when lung cancer patients are progressing
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study suggests that rather than screening for disease, blood tumor markers could be useful in monitoring therapeutic outcomes in those with already established disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 6, 2017 Category: Cancer & Oncology Source Type: news

Roche lung cancer drug Alecensa slashes brain risk in tests
(Reuters) - Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, new clinical trial data show. (Source: Reuters: Health)
Source: Reuters: Health - September 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Jack West, MD: Top Five Lung Cancer Abstracts at ESMO 2017 Jack West, MD: Top Five Lung Cancer Abstracts at ESMO 2017
Lung cancer specialist Dr Jack West previews the most important lung cancer studies being presented at the ESMO 2017 Congress in Madrid.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 5, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
(European Society for Medical Oncology) Data from two separate phase 3 studies to be presented at the ESMO 2017 Congress in Madrid, show alectinib's particular central nervous system (CNS) activity in patients with advanced non-small cell lung cancer involving a mutation of the anaplastic lymphoma kinase gene (ALK-positive NSCLC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 5, 2017 Category: Cancer & Oncology Source Type: news